TrialLeukemia & lymphoma2019
Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis.
John Mascarenhas et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
12 papers cite it
this papercites it
TrialLeukemia & lymphoma2019
John Mascarenhas et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.